Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation
Hurvitz, Sara A., Quek, Ruben G.W., Ettl, Johannes, Rugo, Hope, Bhattacharyya, Helen, Hannah, Alison L., Litton, Jennifer KeatingVolume:
41
Language:
english
Journal:
The Breast
DOI:
10.1016/j.breast.2018.08.080
Date:
October, 2018
File:
PDF, 77 KB
english, 2018